证券代码：600165 股票简称：宁科生物 公告编号：临 2023-052 宁夏中科生物科技股份有限公司 李艳坤女士、李滨先生在担任公司董事期间勤勉尽责、恪尽职守，为公司 规范运作和健康发展发挥了积极作用。公司及董事会对李艳坤女士、李滨先生 在任职期间为公司做出的贡献表示衷心感谢！ 特此公告。 宁夏中科生物科技股份有限公司 董 事 会 二 O 二三年十一月二日 关于非独立董事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁夏中科生物科技股份有限公司（以下简称：公司）董事会于 2023年 10月 31 日分别收到公司非独立董事李艳坤女士、李滨先生提交的书面辞职报告。李 艳坤女士、李滨先生因个人原因，分别向董事会申请辞去公司第九届董事会董 事职务。辞职后，李艳坤女士、李滨先生将不再担任公司任何职务。截至本公 告披露日，李艳坤女士、李滨先生未持有公司股份。 根据《中华人民共和国公司法》及《公司章程》等有关规定，非独立董事 李艳坤女士、李滨先生的辞职未导致公司董事会成员低于法定最低人数，不会 影响公司董事会正常运作，李艳 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥66,620,576.29, a decrease of 49.08% compared to the same period last year[4]. - The net profit attributable to shareholders for the year-to-date period was -¥220,224,822.32, reflecting a decline of 72.18% year-on-year[4]. - The basic and diluted earnings per share for Q3 2023 were both -¥0.122, with a year-to-date figure of -¥0.322[5]. - The net profit for Q3 2023 was -247,882,375.55 RMB, compared to -29,776,569.32 RMB in Q3 2022, indicating a significant decline in profitability[20]. - The total revenue from operating activities was 155,827,411.44 RMB in Q3 2023, down from 707,025,408.18 RMB in Q3 2022, reflecting a decrease of approximately 78%[23]. - The company reported a total comprehensive income of -247,851,414.30 RMB for Q3 2023, compared to -29,473,330.06 RMB in Q3 2022[21]. - Basic and diluted earnings per share for Q3 2023 were both -0.322 RMB, compared to -0.031 RMB in Q3 2022, indicating a worsening performance per share[21]. - The total financial expenses for Q3 2023 were 99,698,875.24 RMB, up from 49,794,319.02 RMB in Q3 2022, representing an increase of approximately 100%[20]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was -¥30,519,828.13, representing a decline of 125.70%[5]. - The operating cash flow for Q3 2023 was -30,519,828.13 RMB, compared to a positive cash flow of 118,752,400.73 RMB in Q3 2022[23]. - Cash and cash equivalents at the end of Q3 2023 were 9,332,768.60 RMB, down from 12,241,217.59 RMB at the end of Q3 2022, showing a decrease of about 24%[24]. - The net cash flow from financing activities for Q3 2023 was 12,481,687.62 RMB, a recovery from a negative cash flow of -106,754,389.14 RMB in Q3 2022[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,136,576,468.24, down 4.33% from the end of the previous year[5]. - Total liabilities as of September 30, 2023, were CNY 2,490,346,797.69, an increase from CNY 2,384,616,750.65 at the end of 2022, representing an increase of approximately 4.4%[16]. - The company's total current assets decreased to CNY 171,992,076.20 from CNY 251,858,363.07, a decline of about 31.6%[14]. - The company's total non-current assets were CNY 2,964,584,392.04, down from CNY 3,026,839,472.43, indicating a decrease of approximately 2.1%[14]. - The company's total equity decreased to CNY 646,229,670.55 from CNY 894,081,084.85, a decline of about 27.8%[16]. - Short-term borrowings increased to CNY 346,792,963.39 from CNY 331,340,167.81, reflecting an increase of approximately 4.4%[15]. - The company reported a net loss of CNY 749,441,968.03 in retained earnings as of September 30, 2023, compared to a loss of CNY 529,217,145.71 at the end of 2022[16]. Operational Highlights - The company reported a significant reduction in sales volume, primarily due to decreased demand for its products[9]. - Total revenue for the first three quarters of 2023 was CNY 168,608,929.26, a significant decrease from CNY 606,123,354.86 in the same period of 2022, representing a decline of approximately 72.1%[19]. - Total operating costs for the first three quarters of 2023 amounted to CNY 397,869,702.37, down from CNY 659,034,504.41 in 2022, indicating a reduction of about 39.6%[19]. - Research and development expenses for the first three quarters of 2023 were CNY 9,839,240.66, compared to CNY 22,767,555.43 in 2022, reflecting a decrease of approximately 56.6%[19]. - The company received government subsidies amounting to ¥390,155.55 during the reporting period, which are related to its normal business operations[7]. - The company has not disclosed any new product developments or market expansion strategies in this report[9]. Impairment and Losses - Non-recurring gains and losses for the year-to-date period totaled -¥7,999,868.08, with a tax impact of -¥3,167,550.80[8]. - The company incurred an asset impairment loss of -25,028,787.09 RMB in Q3 2023, contrasting with a gain of 5,033,130.80 RMB in Q3 2022[20].

证券代码：600165 股票简称：宁科生物 公告编号：临 2023-049 宁夏中科生物科技股份有限公司 第九届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次董事会共三项议案，经审议全部通过。 ● 本次董事会应到董事 10 名，实到董事 10 名。 二、董事会会议审议情况 与会董事对提交本次会议的三项议案进行了认真审议，表决情况如下： （一）审议公司 2023 年第三季度报告（详见上海证券交易所网站 www.sse.com.cn） 一、董事会会议召开情况 （一）本次董事会召开符合有关法律、行政法规、部门规章、规范性文件和 《宁夏中科生物科技股份有限公司章程》的规定。 （二）本次董事会通知于 2023 年 10 月 17 日以电子邮件方式送达，会议材 料于 2023 年 10 月 25 日以电子邮件方式送达。 （三）本次董事会于 2023 年 10 月 27 日上午 9:00 以通讯方式召开。 （四）本次董事会应到董事 10 名，实到董事 10 名。 （五）本次董事会由董事长 ...

娄亦捷 宁夏中科生物科技股份有限公司独立董事 关于第九届董事会第十六次会议相关事项的独立意见 根据《宁夏中科生物科技股份有限公司章程》等有关规定,我们作为宁夏中 科生物科技股份有限公司(以下简称:公司)第九届董事会独立董事,经对相关 资料充分核实后,现就公司第九届董事会第十六次会议审议的《关于续聘信永中 和会计师事务所(特殊普通合伙)为公司 2023 年度审计机构及内部控制审计机 构的议案》发表如下独立意见: 信永中和会计师事务所(特殊普通合伙)(以下简称:信永中和)参与了公 司上市审计及上市以来的相关业务工作,具有从事证券相关业务资格,其在为公 司提供审计服务过程中,严格遵循独立、客观、公正的执业准则,所出具的审计 报告客观、公正地反映了公司的财务状况、经营成果,从会计专业角度维护了公 司和全体股东的利益。综上,我们一致同意续聘信永中和为公司 2023年度审计 机构及内部控制审计机构。 二０二三年十月二十七日 宁夏中科生物科技股份有限公司独立董事关于第九届董事会第十六 次会议相关事项的独立意见签字页: 岳修峰 2017/2019 申屠宝卿 王新灵 2 宁夏中科生物科技股份有限公司独立董事关于第九届董事会第十 ...

宁夏中科生物科技股份有限公司 关于召开 2023 年第三次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600165 证券简称：宁科生物 公告编号：2023-051 网络投票起止时间：自 2023 年 11 月 13 日 至 2023 年 11 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 1 股东大会召开日期：2023年11月13日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、 召开会议的基本情况 网络投票系统：上海证券交易所股东大会网络投票系统 本次股东大会审议议案及投票股东类型 | 序号 | 议案名称 | 投票股东类型 | | --- | --- | --- | | | | 股股东 A | | 非累积投票议案 | | | | 1 | 关于 ...

证券代码：600165 股票简称：宁科生物 公告编号：临 2023-050 宁夏中科生物科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 拟续聘的会计师事务所名称：信永中和会计师事务所（特殊普通合伙）（以下 简称：信永中和）。 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 名 称：信永中和会计师事务所（特殊普通合伙） 成立日期：2012 年 3 月 2 日 组织形式：特殊普通合伙企业 注册地址：北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层 首席合伙人：谭小青先生 截至 2022 年 12 月 31 日，信永中和合伙人（股东）249 人，注册会计师 1,495 人。签署过证券服务业务审计报告的注册会计师人数超过 660 人。 2、投资者保护能力 信永中和已按照有关法律法规要求投保职业保险，职业保险累计赔偿限额和职 业风险基金之和超过 2 亿元，职业风险基金计提或职业保险购买符合相关规定。除 乐视网证券虚假陈述责任纠纷一案之外，信永中和近 ...

本次立案事项系对虞建明先生个人的调查，公司目前生产经营情况正常。在立 案调查期间，虞建明先生将积极配合中国证监会的相关工作，公司将持续关注上述 事项的进展情况，严格按照有关法律、法规的规定履行信息披露义务。 公司指定信息披露媒体为《上海证券报》、《证券时报》，指定信息披露网站为上 海证券交易所网站（www.sse.com.cn），公司发布的信息以在上述指定媒体、网站刊 登的公告为准。敬请广大投资者注意投资风险。 证券代码：600165 股票简称：宁科生物 公告编号：临 2023-048 宁夏中科生物科技股份有限公司 关于实际控制人收到中国证券监督管理委员会 立案告知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁夏中科生物科技股份有限公司（以下简称：公司）接到实际控制人虞建明先 生通知，虞建明先生于 2023 年 9 月 7 日收到中国证券监督管理委员会（以下简称： 中国证监会）下发的《立案告知书》（编号：证监立案字 0342023004 号），因涉嫌信 息披露违法违规，中国证监会决定对虞建明先生立案。 特此公告。 ...

证券代码：600165 股票简称：宁科生物 公告编号：临 2023-047 宁夏中科生物科技股份有限公司 重大诉讼公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 案件所处的诉讼阶段：立案受理，尚未开庭。 ● 是否会对上市公司损益产生负面影响：鉴于案件尚未审理，目前无法准 确判断对宁夏中科生物科技股份有限公司（以下简称：公司）本期利润或期后 利润的影响，最终影响以法院审理结果为准。 ● 法院出具的财产保全裁定书，仅为相关方采取的财产保全措施，公司目 前生产经营情况正常。 一、本次重大诉讼的基本情况 因股权转让合同纠纷，公司控股子公司宁夏中科生物新材料有限公司（以下 简称：中科新材）股东宁夏产业引导基金管理中心（有限公司）（以下简称：产 业基金）作为原告向宁夏回族自治区银川市中级人民法院（以下简称：银川市中 院）提交了《民事起诉状》，对被告上海中能企业发展(集团)有限公司（以下简 称：上海中能）、公司、中科新材提起诉讼。 二、本次重大诉讼的案件当事人、诉讼请求、事实及理由、案件进展情况 （一）案件当事人 ...

宁夏中科生物科技股份有限公司（以下简称：公司）于 2023 年 8 月 24 日收到 公司控股股东上海中能企业发展（集团）有限公司通知，公司实际控制人虞建明先 生曾于 2020 年 7 月因涉及操纵证券市场事项，为配合调查被有权机关采取强制措施， 上海市人民检察院第一分院于 2021 年 3 月 26 日受理该案件，涉及主体为上海中能 企业发展（集团）有限公司、虞建明先生以及其他 6 名自然人，2023 年 3 月 9 日上 海市人民检察院第一分院向虞建明先生出具沪检一分刑不诉【2023】12 号文书："经 本院审查并经二次退回补充侦查，本院仍然认为上海市公安局认定的犯罪事实不清、 证据不足，不符合起诉条件，依照《中华人民共和国刑事诉讼法》第一百七十五条 第四款的规定，决定对虞建明不起诉。"目前上述案件正在审理中，公司将持续关注 上述事项进展情况，严格按照有关法律、法规的规定履行信息披露义务。 公司目前生产经营情况正常，各项工作有序开展。公司指定信息披露媒体为《上 海 证 券 报 》、《 证 券 时 报 》， 指 定 信 息 披 露 网 站 为 上 海 证 券 交 易 所 网 站 （www.sse.com.c ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥101.99 million, a decrease of 78.54% compared to ¥475.30 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2023 was a loss of approximately ¥136.77 million, compared to a profit of ¥8.91 million in the same period last year, representing a decrease of 1,635.28%[18]. - The net cash flow from operating activities for the first half of 2023 was a negative ¥25.31 million, a decline of 361.39% compared to ¥9.68 million in the same period last year[19]. - The basic earnings per share for the first half of 2023 was -¥0.200, compared to ¥0.013 in the same period last year, a decrease of 1,638.46%[20]. - The weighted average return on net assets for the first half of 2023 was -24.383%, a decrease of 25.539 percentage points compared to 1.156% in the same period last year[20]. - The company reported a net loss of ¥154,054,023.08 for the first half of 2023, compared to a net profit of ¥7,241,442.69 in the first half of 2022, indicating a substantial decline in profitability[104]. - The total comprehensive loss for the first half of 2023 was ¥154,033,669.22, compared to a comprehensive income of ¥7,475,957.93 in the same period of 2022[104]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥3.15 billion, a decrease of 3.96% from ¥3.28 billion at the end of the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥492.56 million, down 21.73% from ¥629.31 million at the end of the previous year[19]. - Cash and cash equivalents decreased by 76.21% to ¥21,288,694.26, primarily due to payment of goods[41]. - Accounts receivable financing decreased by 40.26% to ¥1,389,724.25, mainly due to payments made by the subsidiary[41]. - Other current assets decreased by 83.31% to ¥355,307.82, attributed to VAT refund received by the subsidiary[41]. - Total liabilities increased from CNY 2,384,616,750.65 to CNY 2,408,713,236.66, an increase of about 1.01%[96]. - Current liabilities rose from CNY 1,566,516,438.06 to CNY 1,638,307,854.67, an increase of about 4.57%[96]. Operational Insights - The company aims to enhance its profitability by continuously expanding its market share and aligning with market demand[28]. - The company employs a mixed sales model combining direct sales, distribution, and consignment to enhance market penetration[28]. - The procurement process involves selecting multiple suppliers to ensure cost control and stable raw material supply[28]. - The company has detailed the potential risks in the "Management Discussion and Analysis" section of the report[4]. - The company has established a support plan with the local government to help Zhongke New Materials recover from financial difficulties[136]. Environmental Compliance - The company invested nearly 400 million yuan in environmental protection facilities to comply with national regulations and reduce wastewater discharge[57]. - The company has achieved compliance with pollutant discharge standards, with no major environmental issues reported during the reporting period[58]. - The company has implemented various pollution control systems, including advanced technologies for gas and wastewater treatment[59]. - The company has developed a self-monitoring plan for environmental compliance, with third-party assessments confirming that all discharge indicators meet standards[62]. Government Support and Financial Assistance - The company secured special relief funds from the local government to support its subsidiary, which has resumed production[35]. - The company signed a cooperation agreement for financial assistance with the local government to support its subsidiary, Zhongke New Materials[82]. - The company has successfully raised special relief funds through the Shizuishan Huinong District government financing platform to support Zhongke New Materials[68]. Shareholder Information - Total number of common shareholders as of the end of the reporting period is 33,308[86]. - The largest shareholder, Shanghai Zhongneng Enterprise Development (Group) Co., Ltd., holds 200,000,000 shares, accounting for 29.20% of total shares[87]. - The second-largest shareholder, Feng Liang, holds 27,392,229 shares, representing 4.00% of total shares[87]. Legal and Regulatory Matters - The company received a warning letter from the China Securities Regulatory Commission on June 1, 2023, due to regulatory violations, and has implemented corrective measures to enhance compliance awareness[72]. - The company is involved in significant litigation related to financial loan agreements, with Ningxia State-owned Assets Investment Holding Group filing a lawsuit against multiple parties including the company[70]. Financial Management and Accounting Policies - The company’s financial statements are prepared based on the principle of going concern, reflecting its financial position and operating results accurately[138]. - The company’s accounting policies are tailored to its operational characteristics, including revenue recognition and inventory measurement[137]. - The company includes all controlled subsidiaries in the consolidated financial statements, adjusting for any inconsistencies in accounting policies or periods[143]. Research and Development - Research and development expenses decreased by 64.96% to CNY 5.54 million, reflecting reduced investment from the subsidiary[38]. - The company has not reported any new product launches or technological advancements in the current period[127].